They learned various questioning and interviewing techniques, as well as possible ways to assess the veracity of the statements made.

This article examines the degree to which effective supply chains will be a critical success factor for anti-Covid-19 vaccines. While some believe that the potential lack of ampoules, ...

Dr. Hans-Joachim Fritz held a workshop at the Zurich University of Applied Sciences within the scope of their course of studies regarding "CAS Certificate of Advanced Studies/Compliance Investigator."

The IRS Form 990 is more than a tax return, it's a public statement about your nonprofit's financial, programmatic and governance activity for the year.

Microplastics are becoming a growing legal, regulatory, environmental, and reputational risk for consumer...

In this one-hour CLE, we will share timely updates on federal and state enforcement trends that directly affect health...

Takeaways: President Biden's Cybersecurity Executive Order (Video)

Howard Sklamberg, Life Sciences & Healthcare Regulatory partner and former FDA Deputy Commissioner, was recently a guest on NPR's podcast 1A for its episode...

False Claims Act Investigations & Defense partners Craig Margolis, Paula Ramer, Michael Rogoff, and Christian Sheehan presented the firm's annual False Claims Act FY 2023...

In the conference’s opening session, Kevin Toomey (Partner, Chair of Financial Services, Arnold & Porter) and his co-panelist Justin Skidmore (Associate General Counsel, Paxos)...

Arnold & Porter's Financial Services experts will examine the GENIUS Act's impact on banking institutions, analyze recent digital asset sector developments, and discuss the emerging opportunities and challenges facing banks in the evolving cryptocurrency landscape.

Arnold & Porter's False Claims Act (FCA) attorneys recently discussed key takeaways from the September 30, 2024, groundbreaking decision in Zafirov v. Florida Medical Associates LLC, holding the FCA's qui tam device unconstitutional.

This session will provide an overview of the Federal Anti-Kickback Statute, focusing on emerging risks (and mitigation strategies) in the medical device industry.

In an effort to limit challenges for patient access, patient adherence to recommended treatment, or adoption of innovative products and services, providers, suppliers, and product manufacturers seek ways to address such roadblocks.

Our Legislative & Public Policy team is pleased to provide the January 2024 edition of "Capital Snapshot," a monthly summary of the issues, events, and timelines driving federal policy and political decisions.

Our Legislative & Public Policy team is pleased to provide the April 2024 edition of "Capital Snapshot," a monthly summary of the issues, events, and timelines driving federal policy and political decisions.

Our Legislative & Public Policy team is pleased to provide the July 2024 edition of "Capital Snapshot," a monthly summary of the issues, events, and timelines driving federal policy and political decisions.

A significant number of biopharmaceutical companies have recently filed for bankruptcy, often seeking to sell assets through the bankruptcy process, including via section 363 sales.

Our Legislative & Public Policy team is pleased to provide the February 2024 edition of "Capital Snapshot," a monthly summary of the issues, events, and timelines driving federal policy and political decisions.

Our Legislative & Public Policy team is pleased to provide the March 2024 edition of "Capital Snapshot," a monthly summary of the issues...